PMC:4143611 / 20449-21310 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/4143611","sourcedb":"PMC","sourceid":"4143611","source_url":"https://www.ncbi.nlm.nih.gov/pmc/4143611","text":"CD is most commonly treated by surgical removal of the transgressing pituitary adenoma. Reported success rates vary widely and could be a result of surgeon expertise, reliability or timing of assays, or cut-off levels used to define remission. Furthermore, prophylactic measures, such as the use of pre- and/or peri-operative glucocorticoids or steroidogenesis inhibitors may confound results from biochemical assays performed soon after surgery [5]. It has recently been suggested that peri-operative use of glucocorticoids may be unnecessary and that they should be administered only if a biochemical or clinical need is confirmed [5]. Consideration of these variables is important because recurrence of CD following TSS is not uncommon and the current common perception is that post-surgical cortisol levels may predict a patient’s predisposition to relapse.","tracks":[{"project":"2_test","denotations":[{"id":"24980037-20556520-63233451","span":{"begin":447,"end":448},"obj":"20556520"},{"id":"24980037-20556520-63233452","span":{"begin":634,"end":635},"obj":"20556520"}],"attributes":[{"subj":"24980037-20556520-63233451","pred":"source","obj":"2_test"},{"subj":"24980037-20556520-63233452","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ceec93","default":true}]}]}}